American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • New York

PTO grants Argentum IPR petition against PAZEO

American Pharmacy News Reports | Aug 3, 2016
Argentum's has been granted an IPR petition against Alcon's PAZEO.

Argentum Pharmaceuticals recently announced that it, along with its manufacturing partner KVK Tech, has been granted a petition for inter partes review (IPR) against all challenged claims of the sole patent that covers Alcon’s PAZEO by the U.S. Patent & Trademark Office (PTO).  Read More »

Galmed names Dr. Ran Oren Chief Medical Officer

American Pharmacy News Reports | Aug 2, 2016
Galmed has named Dr. Ran Oren its new Chief Medical Officer

Galmed Pharmaceuticals has announced that Professor Ran Oren, M.D., has been named its Chief Medical Officer (CMO).  Read More »

Pfizer announces positive OCTAVE Sustain results

American Pharmacy News Reports | Aug 1, 2016
Pfizer has announced top-of-the-line results for its OCTAVE Sustain study.

Pfizer Inc. recently announced that its third Phase III study of XELJANZ (tofacitinib citrate), Oral Clinical Trials for tofacitinib in ulcerative colitis (OCTAVE) Sustain, has turned in positive result Read More »

Pfizer published Phase 3 crisaborole data

American Pharmacy News Reports | Jul 31, 2016
Pfizer recently published data from two Phase 3 crisaborole studies.

Pfizer Inc. recently published the findings from two pivotal Phase III studies of crisaborole topical ointment 2 percent, formerly known as AN2728.  Read More »

Galmed and SAMIL announce license agreement for Aramchol

American Pharmacy News Reports | Jul 29, 2016
Galmed and SAMIL have announced a license agreement for Aramchol.

Galmed Pharmaceuticals Ltd. and SAMIL Pharm. Co.recently announced that a license agreement has been put into place for an exclusive, royalty-bearing license for Aramchol and its commercialization. Read More »

Cancer vaccine collaboration announced

American Pharmacy News Reports | Jul 28, 2016

Cancer vaccine WO-12 to be developed by Pfizer and Western Oncolytics. Read More »

FDA grants SPK-9001 breakthrough therapy designation

American Pharmacy News Reports | Jul 22, 2016
The FDA has granted SPK-9001 breakthrough therapy designation.

Spark Therapeutics and Pfizer Inc. recently announced that SPK-9001 has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA).  Read More »

WHO prequalifies Pfizer’s MDV for Prevenar 13

American Pharmacy News Reports | Jul 20, 2016
Pfizer's MDV for Prevenar 13 has been prequalified by WHO.

The World Health Organization (WHO) this week prequalified the four-dose, multi-dose vial (MDV) for Pfizer Inc.’s Prevenar 13. Read More »

Positive results from Phase III trial on recurrent renal cell cancer

American Pharmacy News Reports | Jul 18, 2016

Pfizer announces positive results from year-long S-TRAC trial of SUTENT. Read More »

FDA approves Prevnar 13 vaccine for adults ages 18 to 49

American Pharmacy News Reports | Jul 13, 2016

FDA approves expanded age range for the pneumonia vaccine. Read More »

Pfizer announces positive results in Phase III bococizumab studies

American Pharmacy News Reports | Jul 6, 2016

SPIRE-HR and SPIRE-FH lipid-lowering studies meet primary endpoints. Read More »

Health care companies' products honored with Breakthrough Innovation Award

American Pharmacy News Reports | Jun 28, 2016

Nielsen recognizes brands that sustain more than $50 million in first year of sales and maintain 90 percent of the sales level in second year. Read More »

Pfizer acquires Anacor

Amanda Rupp | Jun 27, 2016

Pfizer Inc. recently announced its completed acquisition of Anacor Pharmaceuticals, Inc., giving each outstanding Anacor common stock share the opportunity to gain $99.25 net in cash as part of the acquisition. Read More »

Bristol-Myers Squibb names Murdo Gordon new EVP and chief commercial officer

American Pharmacy News Reports | Jun 22, 2016
Bristol-Myers Squibb has named Murdo Gordon as its new executive vice president and chief commercial officer.

Britol-Myers Squibb recently appointed Murdo Gordon its new EVP and chief commercial officer. Read More »

Pfizer partners with Indiegogo to find healthy aging solutions

American Pharmacy News Reports | Jun 20, 2016

The Pfizer Get Old community and Idiegogo's entrepreneurs invited to submit products or services that support healthy aging. Read More »

Opidivo research detailed at European Hematology conference

American Pharmacy News Reports | Jun 20, 2016

New data has become available from a CheckMate -205 multi-cohort Phase II trial for Bristol-Myers Squibb’s Opdivo this past week. Read More »

Biotie shares delisted from NASDAQ US

American Pharmacy News Reports | Jun 15, 2016

Biotie Therapies Corp. announced on Monday that it has officially delisted its American depository shares (ADS) from the NASDAQ Global Select Market (NASDAQ US). Read More »

Research on XELJANZ to be featured at EULAR 2016

American Pharmacy News Reports | Jun 13, 2016

Pfizer recently announced that several studies and analyses for its tofacitinib citrate (XELJANZ) treatment for rheumatoid arthritis (RA) will be featured at the European League Against Rheumatism Annual Congress (EULAR 2016). Read More »

FDA committees approve ALO-02 capsules

American Pharmacy News Reports | Jun 13, 2016

The U.S. Food and Drug Administration’s (FDA) Advisory Committees has recommended extended-release capsules for ALO-02 from Pfizer. Read More »

Furyk, Pfizer team up to advocate for pneumonia prevention, care

American Pharmacy News Reports | Jun 13, 2016
A visual representation of Streptococcus pneumoniae.

Pfizer announced last week that Jim Furyk has joined the company in advocating awareness for older individuals at risk for infectious diseases, including pneumococcal pneumonia. Read More »

  • «
  • 1
  • 2
  • ...
  • 5
  • 6
  • 7 (current)
  • 8
  • 9
  • 10
  • 11
  • 12
  • »
Trending

Brianna Allen, Senior Director of Public Affairs at PhRMA

PhRMA senior director on 340B program: 'Hospitals abuse the program to boost their profits at the expense of patients'

Molly Jenkins, Director of Public Affairs for PhRMA

PhRMA director of public affairs on 340B exploitation: ‘Evidence shows that 340B entities markup medicines by as much 1,000% or more’

Dan DeNeui, CEO of FarmaKeio

Iowa board files charges against FarmaKeio, citing FDA and California actions

Luke Gale, Revenue Cycle Editor, HealthLeaders Media

HealthLeaders editor on 340B: ‘We continue to have serious concerns about persistent and often illegal abuse of 340B’

Lenora S. Newsome PD Chairperson

Potential medication mix-ups between Inflectra and Zymfentra prompt safety warnings

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up